PDGFR


Also found in: Acronyms.

PDGFRB

A gene on chromosome 5q33.1 that encodes a tyrosine-protein kinase which acts as a cell surface receptor for homodimeric PDGFB and PDGFD and for PDGFA and PDGFB heterodimers, playing a key role in regulating embryonic development; cell proliferation, survival, differentiation, chemotaxis and migration; blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells; and migration of vascular smooth muscle cells and formation of neointima at sites of vascular injury sites. It is required for normal development of the cardiovascular system, for recruitment of mesangial cells and for development of the capillary network in the glomeruli.

PDGFR

PLATELET-DERIVED GROWTH FACTOR receptor.
Mentioned in ?
References in periodicals archive ?
The cells produce the shortened form of the protein by recognizing and using a specific series of nucleotides in the messenger RNA that encodes the instructions to make the PDGFR alpha protein.
Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
Also, stromal expression of PDGFR was associated with shorter overall survival.
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
The problem with targeting normal receptors such as EGFR and PDGFR, is that even though they are expressed at high levels in cancer cells, they are also expressed in some normal tissues.
Therefore, we examined PDGFR and found that the PDGFRs were also upregulated, with increased CF in rat PMCs induced by HG stimulation [Figure 5].
Discovered at Eisai's Tsukuba Research Laboratories and developed in-house, Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR.
Classification of mutations found in hematological malignancies Class I mutations (induce proliferation or inhibit apoptosis) FLT3-ITD, cKit, PDGFR, TEL-PDGFR, FGFR JAK2, JAK3, Bcr-Abl N-Ras, K-Ras p53, NF1 Class II mutations (inhibit differentiation or induce immortalization) Runx 1/AML1, PU1, C/EBP[alpha] MLL fusions, PML-RA[R.
The tumour cells were strong positive for c-kit (CD117), S-100 protein and glial fibrillary acidic protein (GFAP), but did not harbour mutations in the c-kit and PDGFR genes.
The substance STI571, which has been named imatinib, was found to act as a powerful selective inhibitor of tyrosine kinases (c-ABL, BCR-ABL), of PDGFR receptor (platelet derived growth factor receptor) and of c-kit receptor.
Dasatinib, another TKI, is a potent PDGFR inhibitor that causes fluid retention in up to 50% of patients.